Drug Trial Radar · NCT01203917
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: Jan 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,060
Actual
Start
Sep 2010
Primary completion
Aug 2012
Study completion Jun 2016
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 17, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment. Safety data will also be collected and analysed to confirm that treatment with gefitinib is safe and well tolerated.
Conditions
- Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Interventions
GefitinibDrug
250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) (Investigator)Time frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
Locations
61 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Vratsa, Bulgaria
Research Site
Angers, France
Research Site
Saint-Herblain, France
Research Site
Athens, Greece
Research Site
Heraklion, Greece
Research Site
Larissa, Greece
Research Site
Thessaloniki, Greece
Research Site
Budapest, Hungary
Research Site
Deszk, Hungary
Research Site
Edelény, Hungary
Research Site
Győr, Hungary
Research Site
Mosdós, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Ancona, Italy
Research Site
Carpi, Italy
Research Site
Livorno, Italy
Research Site
Perugia, Italy
Research Site
Oslo, Norway
Research Site
Stavanger, Norway
Research Site
Trondheim, Norway
Research Site
Gdansk, Poland
Research Site
Krakow, Poland
Research Site
Lubin, Poland
Research Site
Olsztyn, Poland
Research Site
Otwock, Poland
Research Site
Szczecin, Poland
Research Site
Torun, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland
Research Site
Coimbra, Portugal
Research Site
Lisbon, Portugal
Research Site
Porto, Portugal
Research Site
Vila Nova de Gaia, Portugal
Research Site
Brasov, Romania
Research Site
Bucharest, Romania
Research Site
Cluj-Napoca, Romania
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.